About 58,358 results

ALLMedicine™ Cirrhosis Center

Research & Reviews  18,245 results

Macrophage-specific fibroblast growth factor 12 promotes liver fibrosis progression in ...
Hepatology (Baltimore, Md.); Li S, Zhou B et. al.

Jun 27th, 2022 - Chronic liver diseases are associated with the development of liver fibrosis. Without treatment, liver fibrosis commonly leads to cirrhosis and hepatocellular carcinoma. Fibroblast growth factor 12 (FGF12) is an intracrine factor belonging to the ...

Global Trends and The Impact of Chronic Hepatitis B and C on Disability-Adjusted Life Y...
Liver International : Official Journal of the Internation... Veracruz N, Gish RG et. al.

Jun 27th, 2022 - Advances in hepatitis B virus (HBV) and hepatitis C virus (HCV) therapies have improved morbidity and mortality, but global disparities in viral hepatitis outcomes remain. We evaluate global trends in the impact of HBV and HCV on disability adjust...

Moving CT-based quantification of muscle mass to the mainstream - validation of a web-b...
Liver Transplantation : Official Publication of the Ameri... Hey P, Chew M et. al.

Jun 27th, 2022 - Moving CT-based quantification of muscle mass to the mainstream - validation of a web-based platform to calculate skeletal muscle index in cirrhosis.|2022|Hey P,Chew M,Wong D,Gow P,Testro A,|

Necrotizing Fasciitis In A Patient with Metastatic Clear Cell Ovarian Carcinoma Treated...
The American Journal of Case Reports; Haider A, Gurjar H et. al.

Jun 26th, 2022 - BACKGROUND Necrotizing fasciitis is a life-threatening infection of the deep soft tissues that leads to progressive destruction of the fascia and subcutaneous fat. It typically spreads along the muscle fascia planes because of the relatively poor ...

Journal of Hepatology; Lampertico P, Roulot D et. al.

Jun 26th, 2022 - Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, displaying a superior risk of cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC). Pegylated-Interferon α (pegIFNα), the only off-label therapeutic option that ...

see more →

Guidelines  41 results

EASL Clinical Practice Guidelines on haemochromatosis.
Journal of Hepatology; ,

Jun 7th, 2022 - Haemochromatosis is characterised by elevated transferrin saturation (TSAT) and progressive iron loading that mainly affects the liver. Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropa...

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diag...
Endocrine Practice : Official Journal of the American Col... Cusi K, Isaacs S et. al.

May 16th, 2022 - To provide evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to endocrinologists, primary care clinicians, health care professionals, and other...

EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombos...
Journal of Hepatology; ,

Mar 19th, 2022 - The prevention and management of bleeding and thrombosis in patients with cirrhosis poses several difficult clinical questions. These Clinical Practice Guidelines have been developed to provide practical guidance on debated topics, including curre...

AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients ...
Gastroenterology O'Shea RS, Davitkov P et. al.

Sep 29th, 2021 - AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.|2021|O'Shea RS,Davitkov P,Ko CW,Rajasekhar A,Su GL,|adverse effects,therapeutic use,drug effects,blood,diagnosis,drug therapy,standards,chemical...

AGA Technical Review on Coagulation in Cirrhosis.
Gastroenterology Intagliata NM, Davitkov P et. al.

Sep 29th, 2021 - AGA Technical Review on Coagulation in Cirrhosis.|2021|Intagliata NM,Davitkov P,Allen AM,Falck-Ytter YT,Stine JG,|adverse effects,therapeutic use,drug effects,blood,diagnosis,drug therapy,standards,chemically induced,blood,diagnosis,drug therapy,

see more →

Drugs  645 results see all →

Clinicaltrials.gov  2,375 results

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

Jun 24th, 2022 - We intend to enroll up to 350 subjects with chronic hepatitis C virus (HCV) infection. Subjects will be recruited from two sources: Phase I: treatment naive or experienced who have failed a prior treatment (including DAA-experienced) who are willi...

Seroprevalence of Hepatitis E in People With an Organ Transplant

Jun 24th, 2022 - Hepatitis E virus infection commonly presents as an acute self-limiting hepatitis in the developing world. However there have been reports that chronic hepatitis E may develop in immunocompromised subjects such as renal and liver transplant recipi...

Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis

Jun 24th, 2022 - Hepatitis C (HCV) is a leading cause of cirrhosis worldwide. Most complications associated with cirrhosis are driven by an altered portal circulation and the development of portal hypertension. Bacterial translocation (BT) from the gut to the syst...

Natural History of Noncirrhotic Portal Hypertension

Jun 24th, 2022 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...

Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

Jun 24th, 2022 - At present, there are no clear guidelines as to when antiretroviral therapy for human immunodeficiency virus (HIV) infection should be stopped in the setting of elevated liver enzymes. In large part, this is due to a limited understanding of the n...

see more →

News  1,982 results

Are pain meds the only option for chronic pain in cirrhosis?
Jim Kling

Jun 24th, 2022 - Pain is common in patients with cirrhosis, and its management presents significant challenges to health care providers, such as worries about GI bleeding, renal injury, falls, and hepatic encephalopathy. To address those issues, researchers at the.

HCC with Child-Pugh B cirrhosis: Nivolumab a promising first-line systemic treatment option

Jun 23rd, 2022 - Key clinical point: Nivolumab may serve as a first-line systemic treatment option in patients with hepatocellular carcinoma (HCC) and Child-Pugh B (CP-B) cirrhosis. Major finding: Patients receiving nivolumab vs.

Alcoholic Cirrhosis Is Most Common Liver Transplant Indication in Young US Adults

Jun 22nd, 2022 - NEW YORK (Reuters Health) - Alcohol-associated liver disease is now the most common indication for liver transplant wait-listing among young American adults, researchers say. From 2003 to 2018, the diagnosis of alcoholic liver disease (ALD) as an ...

Rippled Macules and Papules on the Legs
Kieu Oanh Nguyen, MD, Kristopher M. Peters, DO

Jun 7th, 2022 - The Diagnosis: Cutaneous Amyloidosis A punch biopsy confirmed the diagnosis of cutaneous amyloidosis, which is characterized by the deposition of amyloid proteins in the skin without systemic involvement. Subtypes of cutaneous amyloidosis include.

Pseudocirrhosis in breast cancer may signal liver metastases
Jim Kling

Jun 7th, 2022 - CHICAGO – In a large case series of metastatic breast cancer patients with pseudocirrhosis, researchers found that almost all such patients had hormone receptor–positive (HR+) disease as well as extensive liver metastases. Pseudocirrhosis appears.

see more →

Patient Education  55 results see all →